September 28, 2020
This morning Abbott announced that its continuous glucose monitor the FreeStyle Libre 3 earned a CE mark, making it cleared for use for individuals with diabetes living in the European Union. This news comes just a few months after the company landed the much-awaited U.S. FDA clearance for its FreeStyle Libre 2.
Like its predecessor this monitor can also last for 14 days and transmit glucose data...
June 15, 2020
The American Diabetes Association's 80th Scientific Sessions kicked off this weekend, and a handful of diabetes management device-makers and service providers highlighted new data as part of the virtual clinical conference. Read on for summaries of the studies and findings, as well as links to the online abstracts.
Verily-backed diabetes management service Onduo, which combines a mobile app...
June 9, 2020
A new study published in US Endocrinology found Abbott’s continuous glucose monitoring system, the FreeStyle Libre, demonstrated significant cost savings for diabetic care compared to traditional fingerstick testing.
Abbott’s system uses flash continuous glucose monitoring (CGM) through a sensor placed to the back of the upper arm, and lasts for up to 14 days. The device automatically collects...
February 20, 2020
Insulin pump maker Insulin announced partnerships yesterday with two of the leading continuous glucose monitor companies, Abbott and Dexcom. Both involve the Insulet’s Omnipod Horizon Automated Insulin Delivery System which uses a tubeless, wearable “Pod” to deliver insulin for 72 hours at a time.
Abbott and Insulet have partnered to offer a new integrated digital health platform that will...
January 16, 2020
Bigfoot Biomedical, a diabetes startup looking to automate insulin delivery via a connected insulin pen, has kicked off its Series C round with an initial tranche of $45 million. The raise is headed once again by Abbott, with prior backers Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management pitching in once again.
Alongside the news of its raise, Bigfoot...
October 14, 2019
This morning med tech giant Abbott announced a new deal with chronic care management company Omada Health that will integrate Abbott’s FreeStyle Libre continuous glucose monitor (CGM) with Omada's health coaching platform.
Going forward, eligible users with Type 2 diabetes will have the option to integrate data from their FreeStyle Libre, including glucose reading, trends and patterns, with...
September 19, 2019
Sanofi has been active in the digital space this week inking two big deals: one with tech company Abbott and the other with digital platform Happify.
The first partnership with Abbott will combine the medtech company’s FreeStyle Libre, a continuous glucose monitoring system, and the pharma giant’s insulin dosing information to create smart pens and insulin titration apps.
Sanofi is currently...
July 17, 2019
Following a major sales bump in the second quarter of 2019, Abbott Laboratories is planning to significantly ramp up manufacturing for its FreeStyle Libre continuous glucose monitoring system, the company shared during an investor’s call this morning.
Specifically, the company highlighted a 72.9% increase in organic sales growth during the three-month period, reaching a worldwide total sales...
February 20, 2019
Novo Nordisk’s connected insulin pens will integrate with the Abbott Freestyle Libre system, allowing Freestyle Libre users to see data about their insulin alongside their glucose readings, the companies announced this morning.
"Lack of reliable information is a cause of huge frustration for many people with diabetes and their doctors," Anders Dyhr Toft, CVP of commercial innovation at Novo...
December 26, 2018
The pharma industry has become increasingly interested in the digital health space over the last few years, but this quarter numerous projects that have been in the works for years have finally came to fruition. For instance, Pear's reSET, the first digital therapeutic cleared by the FDA, was recently launched to commercial markets.
But that wasn’t the only advance in the space as pharma...